Unknown

Dataset Information

0

Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenstrom macroglobulinemia.

ABSTRACT:

SUBMITTER: Richardson K 

PROVIDER: S-EPMC11059321 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Response and survival predictors in a cohort of 319 patients with Waldenstrom macroglobulinemia treated with ibrutinib monotherapy.
| S-EPMC8945307 | biostudies-literature
Unknown Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia.
| S-EPMC8786275 | biostudies-literature
Unknown Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia.
| S-EPMC6029546 | biostudies-literature
Unknown Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia.
| S-EPMC7484977 | biostudies-literature
Unknown Ibrutinib in Waldenstrom macroglobulinemia: latest evidence and clinical experience.
| S-EPMC4959643 | biostudies-literature
Unknown Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia.
| S-EPMC6234368 | biostudies-literature
Unknown Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive Waldenstrom macroglobulinemia.
| S-EPMC10873534 | biostudies-literature
Unknown Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenstrom Macroglobulinemia on and off Clinical Trials.
| S-EPMC7306303 | biostudies-literature
Unknown CXCL13 levels are elevated in patients with Waldenstrom macroglobulinemia, and are predictive of major response to ibrutinib.
| S-EPMC5664407 | biostudies-literature
Unknown Droplet Digital PCR Assay for MYD88 L265P : Clinical Applications in Waldenstrom Macroglobulinemia.
| S-EPMC7000466 | biostudies-literature